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Abstract
Background: Transforming growth factor type-b (TGF-b)/Smad pathway plays an essential role in vascular fibrosis. Reactive
oxygen species (ROS) generation also mediates TGF-b signaling-induced vascular fibrosis, suggesting that some sort of
interaction exists between Smad and redox pathways. However, the underlying molecular mechanism is largely unknown.
This study aims to investigate the influence of poly(ADP-ribose) polymerase 1 (PARP1), a downstream effector of ROS, on
TGF-b signaling transduction through Smad3 pathway in rat vascular smooth muscle cells (VSMCs).
Methods and Results: TGF-b1 treatment promoted PARP1 activation through induction of ROS generation in rat VSMCs.
TGF-b1-induced phosphorylation and nuclear accumulation of Smad3 was prevented by treatment of cells with PARP
inhibitor, 3-aminobenzamide (3AB) or N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-2-(N,N-dimethylamino)acetami (PJ34), or
PARP1 siRNA. TGF-b1 treatment promoted poly(ADP-ribosy)lation of Smad3 via activation of PARP1 in the nucleus.
Poly(ADP-ribosy)lation enhanced Smad-Smad binding element (SBE) complex formation in nuclear extracts and increased
DNA binding activity of Smad3. Pretreatment with 3AB, PJ34, or PARP1 siRNA prevented TGF-b1-induced Smad3
transactivation and expression of Smad3 target genes, including collagen Ia1, collagen IIIa1 and tissue inhibitor of
metalloproteinase 1, in rat VSMCs.
Conclusions: PARP1 is indispensable for TGF-b1 induced Smad3 activation in rat VSMCs. Targeting PARP1 may be a
promising therapeutic approach against vascular diseases induced by dysregulation of TGF-b/Smad3 pathway.
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Introduction
Transforming growth factor type-b (TGF-b)/Smad pathway is
critical for maintaining normal vascular structure. It regulates
growth, differentiation, migration and proliferation of vascular
cells [1–4]. Dysregulation of TGF-b/Smad pathway may lead to
vascular fibrosis [1–6]. In TGF-b/Smad pathway, activated
receptor-regulated Smads (RSmads), Smad2 and Smad3, mediate
TGF-b signaling from cell membrane to the nucleus to regulate
target gene transcription [7]. Besides RSmads, reactive oxygen
species (ROS) also mediate TGF-b signaling transduction; and
inhibition of ROS generation effectively prevents TGF-b1-
induced over-production of collagens and tissue fibrosis [6,8,9].
These findings suggest that some sort of interaction exists
between Smad and redox pathways in TGF-b signaling
transduction. However, it remains elusive what factor mediates
the interaction.
Poly(ADP-ribose)polymerase-1 (PARP1), an abundant and
ubiquitous nuclear enzyme present in eukaryotes, accounts for
about 90% of total cellular PARP activity. In the nucleus,
activated PARP1 participates in a set of cellular processes by
catalyzing the transfer of ADP-ribose from nicotinamide adenine
dinucleotide (NAD
+) onto nuclear acceptor proteins, including
transcription factors and itself [10–12]. PARP1 can be activated
by DNA strand breaks due to ROS [12,13]. Recently, studies
showed that knockout of PARP1 or suppression of PARP activity
by PARP inhibitor prevented excessive production of collagens
and development of tissue fibrosis under pathological conditions
[10,14–16]. However, the underlying mechanism remains elusive.
Vascular smooth muscle cell (VSMC) is the major cellular
component of blood vessel wall and the major producer of vascular
extracellular matrix (ECM) [17]. We examined the molecular link
and interaction between PARP1 and Smad pathway in TGF-b-
induced mRNA expression of ECM remodeling-related genes in
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prevented TGF-b1-induced PARP1 activation. Knockdown of
PARP1 or inhibition of PARP activity prevented TGF-b1-induced
expression of Smad3 target genes, including collagen I (CoI) a1,
CoIIIa1 and tissue inhibitor of metalloproteinase 1 (TIMP1).
Activation of PARP1 was involved in the regulation of nuclear
accumulation, sequence specific DNA binding and transactivation
of Smad3 in TGF-b1-treated cells.
Results
1. ROS mediated TGF-b1-induced PARP1 activation in
VSMCs
The influence of TGF-b1 on PARP1 activation in VSMCs was
explored. TGF-b1 treatment increased the cellular PARP activity.
Treatment with PARP inhibitor, 3-aminobenzamide (3AB) or
N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-2-(N,N-dimethylamino)
acetamide (PJ34), or PARP1 siRNA prevented TGF-b1-induced
increase in PARP activity of cultured rat VSMCs (Figure 1A). In
line with this result, confocal immunofluoresence assay with anti-
poly(ADP-ribose) polymer (PAR) antibody indicated that TGF-
b1 treatment led to up-regulation of poly(ADP-ribosy)lated
proteins in VSMCs. Inhibition of PARP activity by 3AB or
PJ34 decreased TGF-b1-induced poly(ADP-ribosy)lation levels of
proteins (Figure 1B). Activation of PARP1 increased expression
of its own gene [18,19]. In this study, treatment with 3AB or
PJ34 prevented TGF-b1-induced increase in PARP1 expression
(Figure 1C).
PARP1 can be activated by ROS [12,15]. We demonstrated
that TGF-b1 treatment promoted ROS generation in VSMCs
(Figure 1D); and pretreatment of cells with antioxidant, vitamin C
or N-acetylcysteine (NAC), inhibited TGF-b1-induced increase in
PARP activity (Figure 1E). These results indicated that TGF-b1
activated PARP1 through induction of ROS generation.
2. Inhibition of PARP1 prevented TGF-b1-induced mRNA
expression of Smad3 target genes
TGF-b1 treatment resulted in up-regulation of mRNA levels of
CoIa1, CoIIIa1, TIMP1, matrix metalloproteinase (MMP) 9, but
not of MMP2, in VSMCs (Figure 2A). Knockdown of PARP1 by
siRNA or pretreatment with 3AB or PJ34 inhibited TGF-b1-
induced increase in mRNA expression of above mentioned genes
(Figure 2A), indicating that PARP1 was involved in the regulation
of TGF-b1-induced gene transcription.
Both Smad2 and Smad3 are downstream effectors of TGF-b
signaling. Knockdown of Smad3 by siRNA prevented TGF-b1-
induced transcription of CoIa1 and CoIIIa1 genes, while
knockdown of Smad2 failed to inhibit TGF-b1-induced CoIa1
and CoIIIa1 transcription (Figure 2B), indicating that CoIa1 and
CoIIIa1 were Smad3 target genes. Knockdown of either Smad3
or Smad2 by siRNA inhibited TGF-b1-induced gene transcription
of TIMP1 (Figure 2B), indicating that TIMP1 was the target gene
of both Smad2 and Smad3. However, TGF-b1-induced MMP9
gene transcription was not influenced by Smad2 siRNA or Smad3
siRNA in VSMCs (Figure 2B), suggesting that TGF-b1-induced
MMP9 transcription was not mediated through Smad2/3
pathway. The transcription of CoIa1, CoIIIa1 and TIMP1 were
influenced by several transcription factors. To explore whether the
influences of PARP1 on TGF-b1-induced transcription of these
genes were mediated through Smad3 pathway, both Smad3 and
PARP1 were knocked-down in cells. Results showed that
treatment with PARP1 siRNA failed to influence mRNA
expression of Smad3 target genes in Smad3-knockdown cells
treated with or without TGF-b1 (Figure 2B), implicating that the
effects of PARP1 on TGF-b1-induced transcription of these genes
were mediated through Smad3 pathway.
3. Smad3 were poly(ADP-ribosy)lated by PARP1 in VSMCs
To explore the mechanism underlying the influence of PARP1
on Smad3 target gene transcription, we screened for interacting
nuclear protein of PARP1 by far-western-blot assay using PARP1
protein as probe. Results showed that un-poly(ADP-ribosy)lated
PARP1 (UP-PARP1) specifically bound to a 52 kD protein in
nuclear extracts from TGF-b1-treated VSMCs, but not from non-
treated cells (Figure 3A), indicating that the PARP1-bound 52 kD
protein entered the nucleus after TGF-b1 stimulation. Since
Smad3 was a 52 kD protein and entered the nucleus after
phosphorylation [7,20], this protein was speculated to be Smad3.
In line with this speculation, UP-PARP1 failed to bind to any
52 kD nuclear protein in Smad3-knockdown VSMCs (Figure 3B).
Far-western-blot assay using phosphorylated Smad3 (pSmad3)
protein as probe also showed that pSmad3 could specifically bind
to PARP1 in nuclear extracts (Figure S2A). Thereafter, nuclear
extracts from TGF-b1-treated cells were subjected to co-
immunoprecipitation with antibody specific for PARP1 and
pSmad3 respectively. Western-blot assay revealed that pSmad3
protein was co-immunoprecipitated with anti-PARP1 antibody
(Figure 3C), and vice versa (Figure S2B). In cell-free system, we also
found that pSmad3 could specifically bind to recombinant PARP1
(Figure 3D), and vice versa (Figure S2C).
Whether pSmad3 could be poly(ADP-ribosy)lated by PARP1 in
VSMCs was investigated. TGF-b1 treatment promoted poly(ADP-
ribosy)tion of a 52 kD nuclear protein; and knockdown of PARP1
by siRNA prevented TGF-b1-induced poly(ADP-ribosy)lation of
this protein (Figure S2D). The results indicated that a 52 kD
nuclear protein was poly(ADP-ribosy) lated by PARP1 in TGF-b1-
treated cells. Nuclear extracts were thereafter subjected to
immunoprecipitation with antibody specific for PAR. Western-
blot assay showed that pSmad3 was immunoprecipitated with
anti-PAR antibody (Figure 3C). Immunoprecipitation assay with
antibody specific for pSmad3 was then carried out. Western-blot
assay with anti-PAR antibody revealed that TGF-b1 treatment
increased the amount of eluted poly(ADP-ribosy)lated pSmad3;
and treatment with 3AB or PJ34 prevented TGF-b1-induced
poly(ADP-ribosy)lation of pSmad3 (Figure 3E). In cell free system,
incubation of pSmad3 with active DNA, NAD
+ and PARP1 led to
poly(ADP-ribosyl)ation of pSmad3 (Figure S2E). These results
suggested that TGF-b1 treatment promoted poly(ADP-ribosy)la-
tion of pSmad3 through activation of PARP1.
4. Poly(ADP-ribosy)lation increased the DNA binding of
Smad3
Smad3 can directly bind to Smad-binding element (SBE) in
promoter of target gene. Smad2 participates in DNA-bound
complexes via its interaction with Smad4 [7,20]. The roles of
Smad2 and Smad3 in TGF-b1-induced Smad-SBE complex
formation were explored, respectively. EMSA assay showed that
knock down of Smad2 failed to influnce TGF-b1-induced Smad-
SBEcomplex formation, whileknock down ofSmad3 abrogatedthe
band of Smad-SBE complex (Figure S3A), suggesting that Smad3,
but not Smad2, was the major component of Smad-SBE complex.
In line with this finding, supershift assay showed that incubation of
nuclear extracts from TGF-b1-treated VSMCs with anti-pSmad3
antibody abrogated the band of Smad-SBE complex (Figure 4A).
Interestingly, supershift assay also showed that incubation of anti-
Smad2 or anti-Smad4 antibody with nuclear extracts from TGF-
b1-treated cells failed to abrogate or shift the band of Smad-SBE
complex, although the band intensity of Smad-SBE complex was
PARP1 and TGF-b/Smad3 Pathway
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was used (data not shown). All the data illustrated that Smad3 was a
predominant component of Smad-SBE complex.
The influence of PARP1 on Smad-SBE complex formation was
then investigated. Knockdown of PARP1 by siRNA, or inhibitionof
PARP activity by 3AB or PJ34 prevented TGF-b1-induced Smad-
SBE complex formation in nuclear extracts (Figure 4B, C),
suggesting that activation of PARP1 promoted Smad-SBE complex
formation. Thereby, the direct effect of poly(ADP-ribosy)lation on
Smad-SBE complex formation was investigated. Incubation of
nuclear extracts from non-treated cells with NAD
+ and SBE
increased Smad-SBE complex formation; and this increases were
inhibited by co-incubation with 3AB (Figure 4B). These results
suggested that PARP1 promoted Smad-SBE complex formation
through poly(ADP- ribosy)lation of nuclear proteins.
The effect of poly(ADP-ribosy)lation on Smad3 DNA binding
was explored. With southwestern-blot assay, we demonstrated that
knockdown of Smad3 by siRNA abrogated binding of SBE to a
52 kD nuclear protein, indicating that the SBE-bound 52 kD
protein was Smad3 (Figure S3B). Moreover, southwestern-blot
assay also showed that treatment with TGF-b1 increased the DNA
bindingofSmad3;andtheTGF-b1-inducedincreasewasprevented
when PARP1 was knocked-down by siRNA or inhibited by 3AB or
PJ34 (Figure 4D). Moreover, incubation of nuclear extracts from
non-treated cells with NAD
+ and active DNA also increased Smad3
DNA binding activity; and the increase was inhibited by co-
incubation with 3AB (Figure 4E). Similar results were found in cell
free experiment (Figure S3C). All the data indicated that poly(ADP-
ribosy)lation increased DNA binding of Smad3.
Poly(ADP-ribosy)lation of PARP1 prevented its binding to
DNA. Smad3 could bind to UP-PARP1, but not AP-PARP1,
suggesting that PARP1 was not involved in Smad-SBE complex
formation. In line with this finding, incubation of nuclear extracts
with anti-PARP1 antibody failed to shift or abrogate the band of
Smad-SBE complex (Figure 4A). Moreover, incubation of PARP1
protein with nuclear extracts did not influence Smad3-SBE
complex formation (Figure S3D).
5. Inhibition of PARP1 prevented TGF-b1-induced nuclear
accumulation of Smad3
The influenceof PARP1 on nuclear accumulation of total Smad3
(tSmad3) was explored. Confocal immunofluoresence assay with
Figure 1. ROS mediated TGF-b1-induced PARP1 activation in VSMCs. A. PARP activity was assessed in VSMCs. Cells were pretreated with
vehicles (PBS), 3AB (10 mmol/L, 24 h) or PJ34 (10 mmol/L, 24 h), or transfected with PARP1 siRNA (50 nmol/L, 48 h) or unrelated siRNA (50 nmol/L,
48 h), followed by TGF-b1 (10 ng/ml, 2 h) or vehicles (PBS) treatment. The effect of PARP1 siRNA on PARP1 level was shown in Figure S1. B. Confocal
immunofluorescence assay was used to detect the poly(ADP-ribosy)lated protein expression (green fluorescence) in VSMCs (scale bar=100 mm). Cells
were pretreated with vehicles (PBS), 3AB or PJ34, followed by TGF-b1 or vehicles treatment. Hoechest (blue fluorescence) was used to stain the cell
nuclei. C. Western-blot assay was used to detect PARP1 expression in VSMCs pretreated with vehicles (PBS), 3AB or PJ34, followed by TGF-b1o r
vehicles treatment. D. Intracellular ROS in VSMCs were assessed by DCFH2-DA. Cells were pretreated with vehicles (PBS), NAC (10 mmol/L, 24 h) or
VitC (100 mmol/L, 24 h), followed by TGF-b1 (5, 10 ng/ml, 2 h) or vehicles (PBS) treatment. E. PARP activity was assessed in VSMCs treated as
indicated. Data are expressed as the mean6S.E.M, n=6, ## P,0.01 compared to the control group, ** P,0.01 compared to the TGF-b1 treatment
group.
doi:10.1371/journal.pone.0027123.g001
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increased nuclear tSmad3 levels; and pretreatment with 3AB or
PJ34 preventedthe TGF-b1-induced increase (Figure 5A). Western-
blot assay showed that TGF-b1 treatment increased tSmad3 levels
innuclearextracts,butnotinwholeextracts.Moreover,knockdown
of PARP1 by siRNA or inhibition of PARP activity by 3AB or PJ34
prevented TGF-b1-induced increases in nuclear tSmad3 level, but
did not affected tSmad3 level in whole extracts (Figure 5B).
Following TGF-b stimulation, Smad3 becomes phosphorylated
at carboxyl terminal serine residues (Ser423 and 425) by TGF-b
receptor I (TbRI) and then, enters the nucleus [7,21]. We thereby
investigated the influence of PARP1 on TGF-b1-induced Smad3
phosphorylation. Confocal immunofluoresence assay with anti-
pSmad3 antibody (used to detect levels of Smad3 when
phosphorylated at Ser423/425) showed that TGF-b1 treatment
increased pSmad3 levels in VSMCs, especially in the nucleus; and
Figure 2. Inhibition of PARP1 prevented TGF-b1-induced gene transcription in VSMCs. A. Real-time PCR was used to detect mRNA
expression of CoIa1, CoIIIa1, TIMP1, MMP9 and MMP2 in VSMCs. Cells were pretreated with vehicles (PBS), 3AB (10 mmol/L, 24 h) or PJ34 (10 mmol/L,
24 h), or transfected with PARP1 siRNA (50 nmol/L, 48 h) or unrelated siRNA (50 nmol/L, 48 h), followed by TGF-b1 (10 ng/ml, 2 h) or vehicles (PBS)
treatment. B. mRNA expression of CoIa1, CoIIIa1, TIMP1 and MMP9 in Smad2-knockdown (50 nmol/L, 48 h) or Smad3-knockdown (50 nmol/L, 48 h)
VSMCs. Cells were treated with PARP1 siRNA (50 nmol/L, 48 h) or unrelated siRNA (50 nmol/L, 48 h), followed by TGF-b1 (10 ng/ml, 2 h) treatment.
The effects of PARP1, Smad2 or Smad3 siRNA on levels of PARP1, Smad2 or Smad3 were shown in Figure S1. Data are expressed as the mean6S.E.M.,
n=6,## P,0.01 compared to the control group, ** P,0.01 compared to the TGF-b1 treatment group.
doi:10.1371/journal.pone.0027123.g002
PARP1 and TGF-b/Smad3 Pathway
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increase (Figure 5C). Western-blot assay also showed that TGF-b1
treatment increased pSmad3 levels in whole and nuclear extracts;
and knockdown of PARP1 by siRNA or inhibition of PARP
activity by 3AB or PJ34 prevented TGF-b1-induced pSmad3
increase in both whole and nuclear extracts (Figure 6D). These
results indicated that activation of PARP1 promoted Smad3
phosphorylation in TGF-b1-treated cells.
6. Knockdown of PARP1 prevented Smad3
transactivation
To explore the direct influence of PARP1 on Smad3 target
gene transcription, TIMP1 promoter (from +866bp to +1523bp)
driven luciferase reporter was constructed and transfected
into VSMCs[22]. Treatment with AngII or TGF-b1 increased
luciferase reporter activity in VSMCs, and knockdown of PARP1
by siRNA or inhibition of PARP activity by 3AB or PJ34
prevented the AngII or TGF-b1-induced increase (Figure 6A),
indicating that PARP1 contributed importantly to AngII or TGF-
b1-induced TIMP1 promoter-driven luciferase reporter expres-
sion. Knockdown of either Smad2 or Smad3 prevented AngII or
TGF-b1-induced increase in luciferase reporter activity
(Figure 6B).
To explore the direct influence of PARP1 on Smad3
transactivation, SBE-driven luciferase reporter was constructed
and transfected into VSMCs. Treatment with AngII or TGF-b1
increased luciferase reporter activity in VSMCs; and knockdown
of PARP1 by siRNA or inhibition of PARP activity by 3AB
or PJ34 prevented the TGF-b1 or AngII-induced increase
(Figure 6C). These results indicated that activation of PARP1
mediated AngII or TGF-b1-induced Smad transactivation. To
explore whether Smad2 or Smad3 mediated AngII or TGF-b1-
induced SBE-driven reporter expression, they were knocked down
respectively. Results showed that AngII or TGF-b1 treatment
increased luciferase reporter activity in Smad2-knockdown, but
not Smad3-knockdown, VSMCs. It suggested that activation of
Smad3, but not of Smad2, enhanced the expression of SBE-driven
luciferase reporter gene (Figure 6D). These results also illustrated
that activation of PARP1 was critical for TGF-b1-induced Smad3
transactivation in VSMCs.
Discussion
Transforming growth factor-b (TGF-b)/Smad pathway is an
evolutionarily conserved signaling transduction pathway. Here, we
present the evidence that PARP1 plays a critical role in TGF-b/
Smad3 pathway activation. We demonstrated that activation of
PARP1 was required for TGF-b1-induced Smad3 phosphoryla-
tion and nuclear accumulation. Poly(ADP-ribosy)lation of Smad3
by PARP1 increased its DNA binding activity and promoted
Smad-SBE complex formation in the nucleus. Knockdown of
PARP1 prevented Smad3 transactivation and target gene
transcription.
TGF-b1 stimulation enhances the ROS generation through
activation of NADPH oxidase in cells [6,8,23-25]. PARP1 is a
downstream effector of NADPH oxidase and ROS [26]. We
showed that TGF-b1 treatment increased PARP activity; and
knockdown of PARP1 prevented TGF-b1-induced increase in
PARP activity. This result is consistent with Peter Lonn’s finding
[27]. Under basic condition, PARP1 is a transcriptional repressor
of its own gene since it directly binds to the certain secondary
structures or scaffold/matrix-attachment regions in the promoter
to prevent gene transcription [18,19]. Auto-poly(ADP-ribosy)la-
tion prevents PARP1 binding to the promoter of its own gene and
thereby increases the transcription of itself [18,19]. Thereby, ROS
induced auto-modification of PARP1 enhances PARP1 gene
Figure 3. Phosphorylated Smad3 (pSmad3) was poly(ADP-ribosy)lated by PARP1. A. Far-western-blot assay of nuclear extracts from non-
treated or TGF-b1 treated VSMCs. Un-poly(ADP-ribosy)lated PARP1 (UP-PARP1), auto-poly(ADP-ribosyl)ated PARP1 (AP-PARP1) and b-actin protein
(served as negative control, data not shown) were used as probe, respectively. histone 1 served as loading control (lower panel). B. Far-western-blot
assay was used to detect the binding of PARP1 to pSmad3 in VSMCs transfected with Smad3 or unrelated siRNA (50 nmol/L, 48 h). PARP1 was used as
probe. The effects of Smad3 siRNA on Smad3 levels were shown in lower panel. C. Immunoprecipitation of PAR or PARP1-bound proteins from TGF-
b1-treated VSMCs, followed by western-blot assay using anti-pSmad3 antibody. Unspecific IgG served as negative control. D. Far-western-blot assay
was used to detect the binding of PARP1 to pSmad3 in cell free system. E. Immunoprecipitation of pSmad3 from VSMCs treated as indicated,
followed by western-blot assay using anti-PAR antibody. Total Smad3 and histone 1 served as loading control (data not shown). FWB, far-Western-
blot; IP, Immunoprecipitation; NE, nuclear extracts; WB, Western-blot. Data are expressed as the mean6S.E.M, n=5 to 6. ## P,0.01 compared to the
control group, ** P,0.01 compared to the TGF-b1 treatment group.
doi:10.1371/journal.pone.0027123.g003
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PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e27123Figure 4. Poly(ADP-ribosy)lation increased DNA binding of Smad3. A. Supershift assay of nuclear extracts from TGF-b1-treated VSMCs using
SBE as probe. Lane 2 served as control. Lane 3–6 indicated incubation of nuclear extracts with anti-pSmad3 antibody, anti-PARP1 antibody, anti-PAR
antibodyorunspecificIgG(negativecontrol).B.EMSAassayofnuclearextractsfromVSMCsusingSBEasprobe.Cellswerepretreatedwithvehicles(PBS),
3AB (10 mmol/L, 24 h) or PJ34 (10 mmol/L, 24 h), followed by TGF-b1 (10 ng/ml, 2 h), AngII (0.1 mmol/L, 24 h) or vehicles (PBS) treatment. Lane 9–10
indicated incubation of nuclear extracts from non-treated cells with 10 mM NAD
+ in the absence or presence of 10 mM 3AB. C. EMSA assay of nuclear
extracts from VSMCs using SBE as probe. Cells were transfected with PAPR1 siRNA (50 nmol/L, 48 h) or unrelated siRNA, followed by TGF-b1 (10 ng/ml,
2 h) treatment. The effects of PARP1 siRNA on PARP1 levels were shown in Figure S1. D. Southwestern-blot assay was used to detect SBE binding of
Smad3. VSMCs were treated as indicated. E. Nuclear extracts from non-treated cells were incubated with 3AB, NAD
+/active DNA, or NAD
+/active DNA/
3AB, Southwestern-blot assay was used to detect SBE binding of Smad3. Data are expressed as the mean6S.E.M, n=6. ## P,0.01 compared to the
control group, ** P,0.01 compared to the AngII treatment group, or the TGF-b1 treatment group, or the NAD
+ /active DNA treatment group.
doi:10.1371/journal.pone.0027123.g004
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treatment increased PARP1 expression, and pharmacological
inhibition of PARP activation prevented the TGF-b1 induced up-
regulation of PARP1 expression.
Smad2 and Smad3 are predominantly localized in the
cytoplasm under basic condition [7]. After TGF-b stimulation,
phosphorylated Smad2 or Smad3 forms homomeric or hetero-
meric complexes with Smad4, and enters the nucleus to regulate
gene transcription [7,20]. Our results suggested that PARP1
interacts with Smad3 in nucleus of rat VSMCs under basic
conditions. When PARP1 is activated by TGF-b, it poly(ADP-
ribosy)lates Smad3 and itself thereafter. After poly(ADP-ribosy)
lation reaction, PARP1-Smad3 complex was dissociated and
Smad3 bound to the promoter of its target gene. Although Smad4
could also be poly(ADP-ribosy)lated by PARP1 (Information S1),
the mechanism underlying poly(ADP-ribosy)lation of Smad4 was
different from that of Smad3. Smad4 distributes between nucleus
and cytoplasm under basic condition [28]. We showed that Smad4
could just bind to AP-PARP1, but not UP-PARP1 (Information
S1), indicating that PARP1 did not interact with Smad4 in cells
under basic condition. These findings also suggested that Smad4
might be poly(ADP-ribosy)lated when PARP1 was activated in the
absence of TGF-b stimulation.
Poly(ADP-ribosy)lation is an important post-transcriptional
modification of proteins. It may enhance or inhibit the DNA
binding of different nuclear proteins by changing their respective
structure. For example, the DNA binding activity of PPAR-c
decreased dramatically after poly(ADP-ribosyl)ation [11,12]; on
the contrary, poly(ADP-ribosy)lation enhanced the DNA binding
of AP-1 and NFAT [10,29]. In this study, poly(ADP-ribosy)lation
promoted Smad-SBE complex formation in nuclear extracts and
increased DNA binding activity of pSmad3. Moreover, knock-
down or inhibition of PARP1 prevented TGF-b1-induced increase
in DNA binding of pSmad3. These results suggest a previously
unappreciated possibility that TGF-b1 treatment may increase the
DNA binding of pSmad3 through poly(ADP-ribosy)lation. Smad4
may form heteromeric complex with pSmad3 to regulate target
gene transcription. DNA binding activity of Smad4 was also
increased after poly(ADP-ribosy)lation, suggesting that poly(ADP-
ribosy)lation of Smad4 might also contribute to TGF-b-induced
Smad-SBE complex formation.
Nuclear accumulation of RSmads is a crucial step in TGF-b
signaling transduction [6,30].We showed that activation of PARP1
was required for TGF-b1-induced tSmad3 nuclear accumulation.
Under basic condition, Smad3 translocates into the nucleusthrough
direct association with nuclear import factor importin-b1 and FG-
repeat containing nucleoporins such as CAN/Nup214 [31,32].
After TGF-b stimulation, phosphorylation of Smad3 increases its
nuclear accumulation by destabilizing its interaction with cytoplas-
mic retention factor Smad anchor for receptor activation (SARA)
and enhancing its association with importin-b1 [31,32]. Dephos-
phorylation of Smad2/3 by magnesium-dependent protein phos-
phatase 1alpha (PPM1A) promoted Smad2/3 nuclear export
through induction of Smad2/3 binding to Ran-binding protein 3
(RANBP3) and exportin 4 [7,33,34]. These findings indicate that
nuclear accumulation of Smad3 is phosphorylation dependent [20].
Knockdown or inhibition of PARP1 prevented TGF-b1-induced
increase in pSmad3 in nuclear and whole extracts, indicating that
activation of PARP1 is required for TGF-b1-induced phosphory-
lation of Smad3. These results suggest that PARP1 promotes
tSmad3 nuclear accumulation by increasing its phosphorylation. It
has been demonstrated that phosphorylation levels of Smad3 are
regulated by TbRI, TbRII and PPM1A. Interestingly, knockdown
or inhibition of PARP-1 did not affect the expression of these 3
enzymes in resting and TGF-b1-treated cells (data not shown). In
addition to phosphorylation, interaction between Smad3 and
transcriptional co-activator with PDZ-binding motif (TAZ) may
also affect Smad3 nuclear accumulation [35,36]. However, it is not
clear whether PARP-1 affects the interaction between TAZ and
Smad3. Moreover, the influences of PARP1 on PPM1A, RANBP3
and exportin 4 remained elusive. Thereby, it is necessary to clarify
the detailed mechanism involved in the regulation of Smad3
phosphorylation and nuclear accumulation by PARP-1 in VSMCs.
Activation of Smad3, but not of Smad2, mediated TGF-b1-
induced increase in SBE-driven luciferase activity and transcrip-
tion of CoIa1 and CoIIIa1 genes in VSMCs. Inhibition of PARP1
prevented TGF-b1-induced expression of SBE-driven luciferase
reporter and Smad3 target genes, indicating that activation of
PARP1 was required for TGF-b1-induced Smad3 transactivation.
Besides Smad3 pathway, TGF-b stimulation also leads to ROS
generation through activation of NADPH oxidase [6,8,37,38]. We
found that treatment with antioxidant vitamin C or NAC
prevented TGF-b-induced mRNA expression of Smad3 target
genes, CoIa1 and CoIIIa1, in VSMCs (data not shown). Since
activation of PARP1, a downstream effector of ROS, is required
for TGF-b1-induced Smad3 transactivation and target gene
expression, it is suggested that PARP1 mediates TGF-b1-induced
interaction between redox and Smad3 pathways in VSMCs.
In summary, the data reveal a novel mechanism underlying
activation ofTGF-b/Smad3 signaling pathway inVSMCs:1.TGF-
b stimulation activates PARP1; 2. activation of PARP1 promotes
Smad3phosphorylationandnuclearaccumulation;3.PARP1binds
to and poly(ADP-ribosy)lates pSmad3 in nucleus; 4. poly(ADP-
ribosy)lation promotes binding of Smad3 to its consensus DNA
binding element in the promoter to regulate target gene
transcription. This finding will help us explore the mechanism
underlying involvement of PARP1 in the pathogenesis of vascular
fibrosis. Moreover, it also suggests that PARP1 may be a promising
therapeutic target against vascular fibrosis and other diseases
induced by dysregulation of TGF-b-activated Smad3 signaling.
Materials and Methods
Ethics Statement
All animal work used in this study were conformed to the
National Institutes of Health (NIH) Guide for the Care and Use of
Laboratory Animals, and approved by the Ethics Committee of
Tongji Medical College, Huazhong University of Science and
Technology, China. The permit number of this study is
‘‘[2010]S058’’.
Figure 5. Inhibition of PARP1 prevented TGF-b1-induced nuclear accumulation of Smad3. A and C. Confocal immuno fluorescence assay
was used to detect the expression of total Smad3 (A) and pSmad3 (C) (red fluorescence), respectively. Hoechest (blue fluorescence) was used to stain
the cell nuclei (scale bar=40 mm). Cells were pretreated with vehicles (PBS), 3AB (10 mmol/L, 24 h) or PJ34 (10 mmol/L, 24 h), followed by TGF-b1
(10 ng/ml, 2 h) or vehicles (PBS) treatment. B and D. Western-blot assay was used to detect the expression of total Smad3 (B) and pSmad3 (D) in
VSMCs treated as indicated. Cells were pretreated with vehicles (PBS), 3AB (10 mmol/L, 24 h) or PJ34 (10 mmol/L, 24 h), or transfected with PARP1
siRNA (50 nmol/L, 48 h) or unrelated siRNA (50 nmol/L, 48 h), followed by TGF-b1 (10 ng/ml, 2 h) or vehicles (PBS) treatment. The effects of PARP1
siRNA on level of PARP1 was shown in Figure S1. Data are expressed as the mean S.E.M., n=3. ## P,0.01 compared to the control group, ** P,0.01
compared to the TGF-b1 treatment group.
doi:10.1371/journal.pone.0027123.g005
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Rat vascular smooth muscle cells (VSMCs) were isolated by
enzymatic digestion of thoracic aortic media from male Sprague-
Dawley rats (250–300g, obtained from Tongji Medical College,
HUST) by the method of Michel [39]. Cells were maintained in
DMEM with 20% FBS. The purity of the VSMCs preparation
was evaluated by staining the cells with monoclonal antibodies to
smooth muscle cell a-actin. More than 96% of cells were
immunoreactive. Experiments were performed on cells at 3 to
10 passages after primary culture. In various experiments,
supplements were used at the following concentrations:
10 mmol/L 3AB (Sigma), 10 mmol/L PJ34 (Alexis Biochemicals),
5 or 10 ng/ml TGF-b1 (PeproTech), 0.1 mmol/L AngII (Sigma),
10 mmol/L N-acetylcysteine (NAC, Beyotime, China), 100 mmol/
L vitamin C (Sigma) or the relevant vehicle controls (PBS).
RNA interference and transfection
Small interfering RNA (siRNAs) was synthesized by RiBoBio
Co. Ltd (Guangzhou, China). The sequences of siRNAs were
listed in Table S1. The cultured cells were transfected in 6-well
Figure 6. Inhibition of PARP1 prevented Smad3 transactivation. A and C. Luciferase activity assay was used to detect TIMP1 promoter-driven
luciferase reporter activity (A) or SBE-driven luciferase reporter activity (C) in VSMCs, respectively. Cells were pretreated with vehicles (PBS), 3AB
(10 mmol/L, 24 h) or PJ34 (10 mmol/L, 24 h), or transfected with PARP1 siRNA (50 nmol/L, 48 h) or unrelated siRNA (50 nmol/L, 48 h), followed by
TGF-b1 (10 ng/ml, 2 h), AngII (0.1 mmol/L, 2 h) or vehicles (PBS) treatment. B and D. Luciferase activity assay was used to detect TIMP1 promoter-
driven luciferase reporter activity (B) or SBE-driven luciferase reporter activity (D) in VSMCs. Cells were treated with vehicles (PBS), AngII (0.1 mmol/L,
2 h), TGF-b1 (10 ng/ml, 2 h), or transfected with Smad2 siRNA (50 nmol/L, 48 h) or Smad3 siRNA (50 nmol/L, 48 h) followed by AngII (0.1 mmol/L, 2 h)
or TGF-b1 (10 ng/ml, 2 h) treatment. The effects of Smad2 or Smad3 siRNA on levels of Smad2 or Smad3 were shown in Figure S1. Data are expressed
as the mean 6 S.E.M., n=6, # P,0.05, ## P,0.01 compared to the control group, ** P,0.01 compared to the AngII treatment group or the TGF-b1
treatment group.
doi:10.1371/journal.pone.0027123.g006
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at a final concentration of 50 nmol/L using Lipofectamine 2000
(Invitrogen).
Evaluation of transfection efficiency
VSMCs were plated in 24-well plates 24 hour prior to
transfection with 50 nmol/L Cy3-labeled siRNA as described
above. Transfections were performed in triplicate for each
treatment. One part was fixed for flow cytometric analyses as
previously described [40]. And the others were washed with PBS,
fixed in paraformaldehyde 4% for 30 min in the dark, washed with
methanol for 3 to 5 times, and washed again with PBS. After several
washes inPBS, thecover slips weremounted on PBS/glycerin. Cells
were photographed under a light or fluorescence microscope (for
Cy3, wavelength 555 nm; Olympus Microscope BX-51).
Measurement of intracellular reactive oxygen species
(ROS) levels
The level of intracellular ROS was determined on the basis of
the oxidative conversion of cell permeable 20,70-dichloro
fluorescein diacetate (DCFH-DA) to fluorescent dichloro fluores-
cein (DCF) upon reaction with hydroxyl radical, hydrogen
peroxide, or peroxynitrite. Brie fly, cells were incubated with
control media (PBS) or TGF-b1 in the presence or absence of
antioxidants (NAC or vitamin C) for 2 h. Then cells were washed
twice with cold PBS (pH 7.4) and incubated with DCFH-DA at
room temperature for 30 min in dark. Fluorescent signal was
recorded by using a fluorescence microscopy (488 nm filter;
Olympus Microscope BX-51, Japan). The fluorescence intensity of
eight fields per dish was measured and the reactive oxygen species
(ROS) level was quantified by measurement of fluorescence
intensity with HMIAS-2000 software. Three parallel experiments
were performed. Results were shown as the mean value.
Preparation of whole extracts and nuclear extracts
Whole cell extracts and nuclear extracts were prepared as
described previously [10,11]. Protein extracts were quantitated
using the Bradford assay. The obtained extracts were stored at
280uC until use.
PARP activity assay
PARP activity was assayed using the universal colorimetric
PARP assay kit (Trevigen), based on the incorporation of
biotinylated ADP-ribose onto histone proteins. Cell lysates
containing 50 mg of protein were loaded into a 96-well plate
coated with histones and biotinylated poly ADP-ribose, allowed to
incubate for 1 hour, treated with strep-HRP, and read at 450 nm
in a spectropehotometer.
Western Blot
Equal protein amounts were loaded onto SDS-PAGE gels. After
running gels, proteins were transferred onto nitrocellulose
membranes. Membranes were blocked in 5% nonfat milk and
primary antibody incubations were performed with 3% BSA
(overnight at 4uC). Antibodies used were anti-PARP1 (R&D,
1:1000), anti-PAR (Trevigen, 1:1000), anti-hist1, anti-b-actin
(Santa Cruz, 1:1000), anti-Smad4, anti-Smad3, and anti-phos-
phorylated Smad3 (Cell Signaling Technology, 1:800). Then
membranes were incubated with peroxidase-conjugated secondary
antibody at room temperature for 2 hours. Specific band was
detected with chemiluminescence assay (ECL detection reagents,
Pierce) and recorded on x-ray film. Quantity One software was
used to quantify the intensities of bands.
Real Time RT-RCR
RNA from cultured cells was isolated using Trizol reagent
(TakaraBiotechnology)accordingtothemanufacturer’sinstruction.
cDNA was synthesized using RNA PCR Kit (Takara Biotechnol-
ogy) and used as PCR template. Quantitative PCR was performed
on ABI PRISM 7900 Sequence Detector system (Applied
Biosystems) using SYBR Green I Assay (Takara Biotechnology).
GAPDH was used as endogenous control. Relative gene expression
level (the amount of target, normalized to endogenous control gene)
was calculated using the comparative Ct method formula 2
-DDCt.
The sequences of primers for PCR were listed in Table S2.
Confocal immunofluorescence
Cells seeded on glass chamber slides at a density of 2,000 cells per
chamber were washed, fixed in ice-cold 4% paraformaldehyde for
30 min, and permeabilized in 100 mM phosphate buffer containing
0.2% TritonX-100 (Sigma-Aldrich) for 10 min. The cells were then
incubated with 5% bovine serum albumin (BSA) and immunola-
beled with the indicated antibody (anti-PAR antibody, anti-
phosphorylated Smad3 antibody and anti-Smad3 antibody, respec-
tively) at room temperature for 1 hour. After washing, the cells were
incubated with Alexa Fluor 594 Donkey anti-rabbit IgG or Alexa
Fluor 488 goat anti-mouse IgG (Molecular Probes, Eugene, OR) for
1 hour. After washing, Hoechst (1 mg/ mL; Sigma-Aldrich) was
added to stain the cell nuclei on ice. Cell fluorescence was imaged
on confocal microscope (A1si, Nikon).
In vitro protein-protein interaction assay (far-Western
blot)
Far-western blot assays were performed by resolving protein
samples by SDS-PAGE and transferring them to polyvinylidene-
fluoride membranes. Membranes were then incubated with Hyb-
75 buffer (20 mmol/L HEPES, pH 7.6, 75 mmol/L KCl,
0.1 mmol/L EDTA, 2.5 mmol/L MgCl2, 0.005% Nonidet P-
40, 1 mmol/L DTT) supplemented with 5% non-fat milk,
overnight at 4uC. Membranes were briefly washed with Hyb-75
buffer and then incubated with 1 mg/ml recombinant protein
(PARP1 (Trevigen), pSmad3 (Cell Signaling), or b-actin (Abnova
Corporation) respectively) at room temperature for 1 hour. After
washed with Hyb-75 buffer, membranes were incubated with anti-
PARP1 antibody (1:1000) or anti-Smad3 (1:800) antibody at 4uC
overnight. After washing, membranes were incubated with HRP-
conjugated secondary antibody for 2 hours. Specific bands were
detected using the ECL detection system (Pierce).
Immunoprecipitation assay
Immunoprecipitation assays were performed as described previ-
ously [41]. Briefly, 500 mg of nuclear extracts were incubated with the
indicated antibodies (anti-PARP1, anti-Smad3, anti-PAR, or unspe-
cific IgG respectively) at 4uC for 1 hour, and protein-G agarose at 4uC
for 12 hours. The immunoprecipitates were pelleted by centrifugation
at 5000 g for 1 minute and washed 4 times with lysis buffer. The
pellets were suspended in SDS gel loading buffer, boiled for 10
minutes, and subjected to western blot analysis. To determine the
specificity of the bands, unspecific IgG (negative control) were used.
Electrophoretic Mobility Shift Assay (EMSA) and
Supershift Assay
DNA-protein interaction was detected using LightShift
TM
Chemiluminescent EMSA kit (Pierce) according to the manufac-
turer’s protocol. The sequence of SBE consensus oligonucleotides
was: 59-AGTATGTCTAGACTGA-39. Biotin was labeled at the
59end of the oligonucleotides. In supershift assay, after incubation
PARP1 and TGF-b/Smad3 Pathway
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unspecific IgG at 4uC for 60 minutes, biotin-labeled oligonucle-
otides were added to the reaction and incubated for another 20
minutes.
Southwestern Blot
Southwestern blot was performed according to the procedure of
Butler and Ordahl [42] with slight modifications. Nuclear proteins
(35 mg) were resolved on a 9% SDS-PAGE and then electro-
transferred to a nitrocellulose membrane. Membranes were
blocked with 5% BLOTTO–0.1% bovine serum albumin–
1 mg/ml poly(dI–dC) in binding buffer (30 mM HEPES
(pH 7.6), 1 mM dithiothreitol), followed by incubation with 1.0
pmol biotin-labeled SBE oligonucleotides in Hyb-50 buffer
(30 mmol/L HEPES (pH7.6), 50 mmol/L KCl, 10 mmol/L
MgCl2, 0.1 mmol/L EDTA, 1 mmol/L DTT, 5% BLOTTO,
0.1% bovine serum albumin, and 1 mg/ml poly(dI–dC)) at 4uC
overnight. After washed three times (30 mmol/L HEPES (pH7.6),
50 mmol/L NaCl, 1% BLOTTO), membranes were incubated
with streptavidin-horseradish peroxidase conjugate in blocking
buffer (Pierce) for 15 min. Specific binding was detected with ECL
detection reagents (Pierce) and band intensities were quantified as
described above.
Luciferase assay
A 0.6-kb promoter fragment (spanning from +866 bp to +1523
bp) from the rat TIMP1 gene was cloned by PCR from rat
genomic DNA and inserted into the NheI/XhoI cut pGL3 basic
luciferase expression vector (Promega) according to the procedure
of El-Sayed Akool et al[22]. The complementary oligonucleotides
used for pSBE2-luc (with two copies of SBE) construction were
sence: 59-TAAGTCTAGACGGCAGTCTAGAC-39, and anti-
sence: 59-TCGAGTCTAGACTGCCGTCTAGACTTAGTAC-
39. The complementary oligonucleo- tides were inserted into the
KpnI/Xho-I cut pGL3- promoter luciferase expression vector
(Promega). VSMCs were transiently transfected by use of
Lipofectamine 2000 (Invitrogen) in accordance with the manu-
facturer’s instruction. After incubation for 24 hours, cells were
harvested, lysed, and assayed for luciferase activity with Dual
Luciferase Reporter Assay Kit (Promega) according to the
manufacturer’s instruction.
Statistic analysis
Values are shown as mean6SEM of at least three independent
experiments. The significance of differences was estimated by one-
way ANOVA followed by Student-Newmann-Keuls multiple
comparison tests. P,0.05 was considered significant. All statistical
analyses were performed with SPSS software (version 11.0, SPSS
Inc).
Supporting Information
Figure S1 Evaluation of siRNA transfection effiency in
VSMCs. A. Insets show a magnification (40T) of VSMCs
transfected with Cy-3-labeled siRNA as indicated concentration
(10, 20, 50 nmol/L, 48 h) by light microscopy (upper panel) and
fluorescence microscopy (lower panel). B. VSMCs transfected with
vehicle or Cy-3-labeled siRNA as indicated concentration (10, 20,
50 nmol/L, 48 h) were analyzed with flow cytometry. C, D, E. The
effects of PARP1 siRNA (50 nmol/L, 48 h) (C), Smad3 siRNA
(50 nmol/L, 48 h) (D) and Smad2 siRNA (50 nmol/L, 48 h) (E) on
levels of PARP1, Smad3 and Smad2 were analyzed by western blot,
respectively. Unrelated siRNA served as negative control. Data are
expressedas themean6S.E.M, n=6.## P,0.01 compared to the
control group.
(TIF)
Figure S2 Phosphorylated Smad3 (pSmad3) was poly
(ADP-ribosy)lated by PARP1. A. Far-western-blot assay was
used to detect the binding of PARP1 to pSmad3 in VSMCs
transfected with PARP1 or unrelated siRNA (50 nmol/L, 48 h).
pSmad3 was used as probe. The effects of PARP1 siRNA on
Smad3 levels were shown in lower panel. B. Immunoprecipitation
of pSmad3-bound proteins from TGF-b1-treated VSMCs,
followed by western-blot assay using anti-PARP1 antibody.
Unspecific IgG served as negative control. C. Far-western-blot
assay was used to detect the binding of PARP1 to pSmad3 in cell
free system. D. Poly(ADP-ribosy)lation levels of 52 kD nuclear
protein were assessed by western-blot assay using anti-PAR
antibody. histone 1 served as loading control. E. Western-blot
assay with anti-PAR Ab was used to detect the poly(ADP-
ribosy)lation levels of pSmad3, Smad4 or p65 in cell-free system.




DNA/3AB or PARP-1. Data are expressed as the mean6S.E.M,
n=6. ## P,0.01 compared to the control group. ** P,0.01
compared to the TGF-b1 treatment group.
(TIF)
Figure S3 Poly(ADP-ribosy)lation increased DNA bind-
ing of Smad3 and Smad4. A. EMSA assay of nuclear extracts
from Smad2-knockdown (50 nmol/L, 48 h) or Smad3-knockdown
(50 nmol/L, 48 h) VSMCs using SBE as probe. Cells were
pretreated with vehicles (PBS) or 3AB (10 mmol/L, 24 h),
followed by TGF-b1 (10 ng/ml, 2 h) or vehicles (PBS) treatment.
B. Southwestern-blot assay was used to detect SBE binding of
Smad3. VSMCs were treated as indicated. C. South-Western-blot
assay was used to detect the DNA binding activity of Smad3,
Smad4 or PPAR-c in cell-free system. Recombinant pSmad3,
Smad4 or PPAR-c were incubated with vehicles, PARP1/NAD
+/
active DNA, PARP1/NAD
+/active DNA/3AB or PARP1. D.
EMSA assay using SBE as probe. Lane 1–2 indicated incubation
of nuclear extracts with recombinant PARP1 protein (1:40, 1:20).
Lane 4 indicated incubation of nuclear extracts with unspecific
IgG. Lane 3 served as control. E. Southwestern-blot assay was
used to detect SBE binding of Smad4. VSMCs were treated as
indicated. F. Nuclear extracts were incubated with 3AB, NAD
+/
active DNA, or NAD
+/active DNA/3AB. Southwestern-blot assay
was used to detect SBE binding of Smad4. The effects of Smad2,
Smad3 and Smad4 siRNA on levels of Smad2, Smad3 and Smad4
were shown in Figure S1. Data are expressed as the mean6S.E.M,
n=6. ## P,0.01 compared to the control group, ** P,0.01
compared to the NAD
+ /active DNA treatment group.
(TIF)
Information S1 Poly(ADP-ribosy)lation increased the
DNA binding of Smad4.
(DOC)
Table S1 The sequences of siRNAs used in this study.
(DOC)
Table S2 The sequences of primers for real time RT-
PCR used in this study.
(DOC)
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